Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV Bladder Cancer
Stage IV bladder cancer is defined by the following TNM classifications:
T4b, N0, M0
Any T, N1–N3, M0
Any T, Any N, M1
Currently, only a small fraction of patients with stage IV bladdercarcinoma can be cured. The potential for cure is restricted to patients with stage IV disease with involvement of pelvic organs by direct extension or metastases to regional lymph nodes. These patients may undergo radical cystectomy with pelvic lymph node dissection. The extent of lymph node dissection during cystectomy is controversial  as there are no data from prospective trials demonstrating improved outcomes with lymph node dissection. Definitive radiation therapy with or without concurrent chemotherapy, evaluated mainly in patients with locally advanced (T2–T4) disease, appears to have minimal curative potential in patients with regional lymph node metastases.
To prevent bladder cancer, your best bet is to avoid possible carcinogens, or cancer-causing substances. For starters, don't smoke. Eat smoked or cured meats only occasionally and prepare fresh rather than processed foods.
Research also suggests that there is a reduced incidence of bladder cancer among people with adequate vitamin B-6, beta-carotene, and selenium in their diets. If you work around carcinogenic chemicals, follow safety guidelines to avoid undue exposure. And if you feel you may be...
Prognosis is so poor in patients with stage IV disease that consideration of entry into a clinical trial is appropriate. The focus of care for many stage IV patients is on palliation of symptoms from bladder tumor that is often massive. Urinary diversion may be indicated, not only for palliation of urinary symptoms, but also for preservation of renal function in candidates for chemotherapy. Platinum-based combination chemotherapy regimens are the standard of care. A prospective, randomized trial of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) compared with cisplatin, cyclophosphamide, and doxorubicin demonstrated improved response and median survival rates (48 weeks vs. 36 weeks, P = .003) with the former regimen. Results from a randomized trial that compared M-VAC with single-agent cisplatin in advanced bladder cancer also showed a significant advantage with M-VAC in both response rate and median survival (12.5 months vs. 8.2 months, P = .002). The (outpatient) regimen of paclitaxel and carboplatin achieved response rates in the range of 50% in single-institution phase II trials.[5,6][Level of evidence: 3iiiDiv] However, when this regimen was evaluated in a multicenter phase II study conducted by the Southwest Oncology Group, the response rate was only 21%.[Level of evidence: 3iiiDiv] Gemcitabine has shown activity in phase II trials of patients with metastatic bladder cancer. In a multicenter, randomized, phase III trial comparing the combination of gemcitabine/cisplatin (GC) with the M-VAC regimen in 405 patients with advanced or metastatic bladder cancer, GC yielded similar response rates, time-to-progression, and overall survival (OS) (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.82–1.32; P = .75) compared with M-VAC, but GC had a better safety profile and was better tolerated than M-VAC. Although this study was not designed to show the equivalence of the two regimens, the similar efficacy and reduced toxic effects of GC make it a reasonable alternative in patients who may not tolerate the M-VAC regimen.[Level of evidence: 1iiA]